Pharmaceuticals & Therapeutics

Vertex's new CF drug, ALYFTREK, clears a major hurdle in Canada, promising a once-daily treatment and new hope for patients previously left behind.

With a breakthrough oral drug for a rare form of blindness, Belite Bio heads to a key symposium. Can it convince investors it can win a crowded race?

A South Korean biotech's diabetes drug finds new purpose in fighting FSHD, backed by a foundation's innovative funding model that could reshape rare disease R&D.

After a Health Canada-mandated pause, LSL's Steri-Med is near full remediation. This is more than a fix—it’s a calculated play for North American market leadership.

Australian biotech Immuron hires a top dealmaker to land a partner for its novel C. diff therapy. The goal: secure funding and unlock a potential $400M market.

UK biotech Ananda Pharma advances its MRX1 drug to Phase 2 trials, targeting a debilitating chemotherapy side effect with no current effective treatment.

A $250 credit for hormone therapy seems generous, but a closer look at SynergenX's '250 for 250' initiative reveals a sophisticated marketing strategy.

At Boston's Wedbush Renal Summit, Hansa Biopharma showcases its game-changing transplant drug, signaling a major strategic play for the lucrative U.S. market.

A massive financing round for deupirfenidone isn't just about a potential new IPF drug; it's a masterclass in biotech strategy, validating a model that promises value for all.

A new study for CRENESSITY could revolutionize care for infants with classic congenital adrenal hyperplasia, shifting the treatment paradigm and solidifying market leadership.

Advicenne's unlimited UK drug approval for Sibnayal® is a win for rare disease patients, but it's one piece in a high-stakes global strategy now targeting the US market.

Artelo's latest data on its non-opioid pain drug ART26.12 could unlock a massive market, but what are the real risks and rewards for this clinical-stage biotech?

Vyome Holdings secures a key patent in China, not by betting the farm, but by making a shrewd, capital-efficient move to tap into a massive future market.

New imaging data provides the first evidence that a drug-app combo for Parkinson's can induce physical changes in the brain, linking digital therapy to better outcomes.

Galderma's innovative neuromodulator, a key to its 'powerhouse' ambitions, hits a U.S. roadblock. The FDA's concerns? Manufacturing, not safety.

The FDA approved Orca Bio's revolutionary cell therapy, promising better outcomes for cancer patients. But the real test lies beyond the science.

The FDA's approval of a potent new triglyceride drug comes with a staggering price tag, forcing a showdown with an established, affordable therapy.

Millions suffer from chronic cough with no cure. A Boston biotech is testing a novel aerosol that targets the root cause, not just symptoms. Could it be the first disease-modifying treatment?

Kowa's pemafibrate gets FDA Breakthrough status for a rare liver disease. We dissect what this means for patients, the science, and the company's global strategy.

Artelo Biosciences uses advanced analytics to link its lead drug to a core disease pathway, a strategic move to de-risk development and attract major partners.